TMCnet News

Independent Study Highlights the Importance of Molecular Testing in Predicting Biologic Behavior of Pancreatic Cysts
[October 31, 2014]

Independent Study Highlights the Importance of Molecular Testing in Predicting Biologic Behavior of Pancreatic Cysts


PITTSBURGH --(Business Wire)--

RedPath Integrated Pathology, Inc., a leader in molecular diagnostics, announced today the publication of a peer-reviewed, independent study supporting the importance of mutational profiling in predicting the biologic behavior of pancreatic cysts.

The study, published in the Journal of the Pancreas, aimed to evaluate whether EUS imaging, CEA, and cytology combined with genetic analyses should be used to better predict the malignant potential of pancreatic cysts. An online version of the publication can be accessed viewed at: http://www.serena.unina.it/index.php/jop/article/view/2426/2819.

Led by researchers from Harbour UCLA Medical Center in Torrance, CA (News - Alert), the study, "…strongly supports the value of molecular testing of pancreatic cyst fluid in predicting cyst behavior." In addition, the results, "…demonstrate a significant agreement between molecular diagnosis of PathFinderTG and malignantpotential of pancreatic cysts."



The study shows that mutational profiling can aid in the detection of malignant disease and provide reliable evidence for benign disease. Based on the results, the authors recommend surveillance and surgery patient management strategies that incorporate use of mutational profiling.

"This new study provides additional evidence that mutational profiling is very useful at predicting malignancies in pancreatic cysts, and that using PathFinderTG can make an improved difference in patient management," stated Dennis M. Smith, Jr., M.D., president and chief executive officer of RedPath Integrated Pathology.


About PathFinderTG

RedPath's patented PathFinderTG Pancreas profile uses LOH markers, oncogene mutations, and DNA content abnormalities to evaluate pancreatic cystic lesions and integrate these analyses with clinical features to accurately risk stratify patients for the development of pancreatic adenocarcinoma. PathFinderTG has been demonstrated to be superior to standard first-line tests for risk stratification. All patients, except those with a malignant diagnosis on cytology, are ideal candidates for testing with PathFinderTG.

About RedPath Integrated Pathology

RedPath Integrated Pathology, Inc. is a Pittsburgh-based molecular diagnostics laboratory focused on providing novel solutions for clinicians. RedPath's patented PathFinderTG® platform produces mutational profiles to help physicians resolve complex diagnostic dilemmas in patients who are at risk of cancer. RedPath performs all clinical testing and R&D in its state-of-the-art, CLIA-certified and CAP-accredited laboratory.

The PathFinderTG platform is supported by more than 20 years of scientific and clinical research, and studies using it have been published in more than 200 peer-reviewed journals, including The New England Journal of Medicine. Based on the strong clinical data supporting this platform, RedPath has received positive coverage decisions from Medicare and private payers. For more information about RedPath Integrated Pathology visit www.redpathip.com or contact Andrew Mignatti at 412-224-6100.


[ Back To TMCnet.com's Homepage ]